CO2023001411A2 - Inhibidores del factor c3 del complemento y sus usos médicos - Google Patents

Inhibidores del factor c3 del complemento y sus usos médicos

Info

Publication number
CO2023001411A2
CO2023001411A2 CONC2023/0001411A CO2023001411A CO2023001411A2 CO 2023001411 A2 CO2023001411 A2 CO 2023001411A2 CO 2023001411 A CO2023001411 A CO 2023001411A CO 2023001411 A2 CO2023001411 A2 CO 2023001411A2
Authority
CO
Colombia
Prior art keywords
compstatin
introduction
modifications
inhibitors
analogues
Prior art date
Application number
CONC2023/0001411A
Other languages
English (en)
Spanish (es)
Inventor
Anne Pernille Tofteng Shelton
Henrik Fischer Munch
Rasmus Leth
Original Assignee
Zp Spv 3 K/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zp Spv 3 K/S filed Critical Zp Spv 3 K/S
Publication of CO2023001411A2 publication Critical patent/CO2023001411A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
CONC2023/0001411A 2020-07-16 2023-02-09 Inhibidores del factor c3 del complemento y sus usos médicos CO2023001411A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20186297 2020-07-16
PCT/EP2021/069798 WO2022013374A1 (en) 2020-07-16 2021-07-15 Inhibitors of complement factor c3 and their medical uses

Publications (1)

Publication Number Publication Date
CO2023001411A2 true CO2023001411A2 (es) 2023-02-16

Family

ID=71661768

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0001411A CO2023001411A2 (es) 2020-07-16 2023-02-09 Inhibidores del factor c3 del complemento y sus usos médicos

Country Status (11)

Country Link
US (1) US20230287051A1 (cg-RX-API-DMAC10.html)
EP (1) EP4182023A1 (cg-RX-API-DMAC10.html)
JP (1) JP2023538807A (cg-RX-API-DMAC10.html)
KR (1) KR20230039718A (cg-RX-API-DMAC10.html)
CN (1) CN116209671A (cg-RX-API-DMAC10.html)
AU (1) AU2021309548A1 (cg-RX-API-DMAC10.html)
CA (1) CA3185730A1 (cg-RX-API-DMAC10.html)
CO (1) CO2023001411A2 (cg-RX-API-DMAC10.html)
IL (1) IL299870A (cg-RX-API-DMAC10.html)
MX (1) MX2023000679A (cg-RX-API-DMAC10.html)
WO (1) WO2022013374A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020017385A2 (pt) 2018-02-27 2020-12-15 Zp Spv 3 K/S Análogos de compstatina, métodos e seus usos médicos
KR20240118914A (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
CA3231953A1 (en) 2021-09-15 2023-03-23 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
EP4622992A1 (en) * 2022-11-24 2025-10-01 Amyndas Pharmaceuticals US LLC Compstatin analogs for vector-based therapy
CN118812653A (zh) * 2023-04-18 2024-10-22 成都奥达生物科技有限公司 一种长效坎普他汀化合物
CN119219741A (zh) * 2023-06-29 2024-12-31 刘晓蓉 新型补体抑制剂及其制备、应用和产品
CN122255228A (zh) * 2024-12-20 2026-06-23 重庆派金生物科技有限公司 靶向抑制c3与c5补体的双功能多肽、多肽偶联物及它们的应用
US20260234189A1 (en) 2025-01-24 2026-08-13 Boehringer Ingelheim International Gmbh Novel and stable compstatin analogues

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000505068A (ja) 1996-03-13 2000-04-25 トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア 補体活性化を阻害する新規ペプチド類
CZ295838B6 (cs) 1996-09-09 2005-11-16 Zealand Pharma A/S Způsob výroby peptidů
WO1999013899A1 (en) 1997-09-17 1999-03-25 Trustees Of The University Of Pennsylvania Peptides and peptidomimetics for inhibiting complement activation
US7989589B2 (en) 2002-09-20 2011-08-02 The Trustees Of The University Of Pennsylvania Compstatin analogs with improved activity
CN101325963B (zh) 2005-10-08 2016-01-27 博泰迪亚制药公司 用于眼部病症的补体抑制素和其类似物
ES2390828T3 (es) 2005-11-28 2012-11-16 The Trustees Of The University Of Pennsylvania Análogos potentes de la compstatina
WO2008153963A1 (en) 2007-06-08 2008-12-18 The Trustees Of The University Of Pennsylvania Structure of compstatin-c3 complex and use for rational drug design
CA2813049A1 (en) * 2010-09-23 2012-03-29 The Trustees Of The University Of Pennsylvania Modified compstatin with improved stability and binding properties
EP2751161B1 (en) * 2011-08-31 2018-09-19 Huntsmann Advanced Materials Licensing (Switzerland) GmbH Process for the impregnation of air core reactors, impregnated air core reactor and use of an impregnation system
PL2753636T3 (pl) 2011-09-07 2020-05-18 The Trustees Of The University Of Pennsylvania Analogi kompstatyny o ulepszonych właściwościach farmakokinetycznych
WO2014100407A1 (en) 2012-12-19 2014-06-26 The Regents Of The University Of California Compstatin analogs
US10213476B2 (en) * 2014-03-17 2019-02-26 The Trustees Of The University Of Pennsylvania Compstatin analogs with improved potency and pharmacokinetic properties
BR112020017385A2 (pt) * 2018-02-27 2020-12-15 Zp Spv 3 K/S Análogos de compstatina, métodos e seus usos médicos
ES3049784T3 (en) * 2019-08-27 2025-12-18 Zp Spv 3 K/S Compstatin analogues and their medical uses

Also Published As

Publication number Publication date
US20230287051A1 (en) 2023-09-14
CA3185730A1 (en) 2022-01-20
EP4182023A1 (en) 2023-05-24
MX2023000679A (es) 2023-04-18
CN116209671A (zh) 2023-06-02
JP2023538807A (ja) 2023-09-12
KR20230039718A (ko) 2023-03-21
WO2022013374A1 (en) 2022-01-20
AU2021309548A1 (en) 2023-02-23
IL299870A (en) 2023-03-01

Similar Documents

Publication Publication Date Title
CO2020011027A2 (es) Análogos de compstatina y sus usos médicos
MX2023000679A (es) Inhibidores del factor c3 del complemento y sus usos medicos.
CO2022003556A2 (es) Análogos de compstatina y sus usos médicos
DOP2021000197A (es) Composición farmacéutica, que comprende la variante de hialuronidasa ph20 humana y fármaco, para inyección subcutánea
MX2019006515A (es) Composiciones que comprenden peptido wkdeagkplvk.
ES2572260T3 (es) Péptidos útiles en el tratamiento y/o cuidado de la piel y/o membranas mucosas y su uso en composiciones cosméticas o farmacéuticas
MX2009012675A (es) Tensioactivos reconstituidos que tienen propiedades mejoradas.
EA202190960A1 (ru) Конденсированные пирролины, которые действуют как ингибиторы убиквитин-специфической протеазы 30 (usp30)
ES2651946T3 (es) Utilización de péptidos CD31 en el tratamiento de trastornos trombóticos y autoinmunes
MX2009004147A (es) Vacunas de peptido para canceres que expresan polipeptidos mphosph1 o depdc1.
EA201190292A1 (ru) Улучшенная композиция реконструированных сурфактантов, содержащая аналоги сурфактантного белка в (sp-b) и сурфактантного белка с (sp-c)
CY1113948T1 (el) Θεραπευτικα δραστικα αλφα-msh αναλογα
CL2021000938A1 (es) Composiciones estables de semaglutida y usos de las mismas
PE20090682A1 (es) Secuencias peptidicas y composiciones
EA202192555A1 (ru) Комбинированная терапия для лечения рака
CL2019003441A1 (es) Puestos de mic-1 y usos de estos.
CU20220066A7 (es) Péptidos inmunogénicos útiles en el tratamiento de esclerosis múltiple
AR092279A1 (es) Pirrol carboxamidas fluorometilo sustituidas
BR112022008087A2 (pt) Composições tensoativas concentradas substancialmente anidras
PE20190375A1 (es) Inhibidor de esterasa c1 conjugado y sus usos
EA202192793A1 (ru) Композиция для пероральной доставки белков, пептидов и малых молекул со слабой проницаемостью
CL2023002583A1 (es) Ligandos peptídicos del receptor 3 de somatostatina restringidos conformacionales y sus conjugados y sus usos.
ATE342914T1 (de) Peptidanaloge als selektive inhibitoren der thrombinaktivierung des durch protease aktivierten rezeptors
CO2024008344A2 (es) Péptidos lipolíticos
EA202092190A1 (ru) Композиции и способы для лечения сильного запора